Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OPK vs WGS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OPK Captures Overall Composite Edge (38.6 SELL vs 49.5 HOLD), While WGS Leads 5–1 on Growth & Valuation Pillars

OPK Overall Winner 6-Pillar Tally: OPK 1 – 5 WGS Matrix Metrics: OPK 5 – 5 WGS

As of Nov 16, 2026, Opko Health Inc. (OPK) captures the overall head-to-head institutional edge over GeneDx Holdings Corp. (WGS) on higher Unified Composite conviction (38.6/100 SELL vs. 49.5/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale), while WGS wins 5–1 across the 6-pillar growth and valuation breakdown. OPK trades at $1.62 (53.8x Forward P/E, -27.8% operating margin) versus WGS at $51.02 (40.6x Forward P/E, -13.7% operating margin).

  • Composite vs. Pillar Nuance: While WGS currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. OPK 38.6/100 SELL), OPK captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (-27.8% vs. -13.7% operating margin) and revenue trajectory (+15.9% vs. +5.4% YoY).
  • Technical & Structure Timing Caution: OPK trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.0); meanwhile WGS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OPK vs WGS
OPK NASDAQ Head-to-Head Winner
Opko Health Inc.
Pharmaceutical Preparations
$1.62
-3.57% 1D
Market Cap $1.2B
TTM Revenue $654M
Forward P/E 53.8x
Beta / 30D Vol 0.77β · 31% Vol
Unified Composite Score
38.6 / 100 SELL
Tech 30.0 Fund 43.0 Flow 65.0 Mom 36.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $1.67 · SMA50: $1.60
WGS NASDAQ
GeneDx Holdings Corp. Class A Common Stock
Services-Health Services
$51.02
-2.58% 1D
Market Cap $1.6B
TTM Revenue $461M
Forward P/E 40.6x
Beta / 30D Vol 1.74β · 111% Vol
Unified Composite Score
49.5 / 100 HOLD
Tech 33.0 Fund 53.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.3%), weak momentum, RSI 35
RSI-14: 34.8 · SMA20: $62.47 · SMA50: $73.13

6-Pillar Scorecard Institutional Category Breakdown (OPK 1 – 5 WGS)

Columns: Metric · OPK · WGS
1. Valuation Multiples WGS
Forward P/E 53.8x 40.6x
Trailing P/E 53.8x 38.8x
PEG Ratio N/M N/M
EV / Revenue 2.1x 3.7x
2. Growth & Scale OPK
Revenue Growth (YoY) +15.9% +5.4%
Earnings Growth (YoY) -12.6% +0.0%
TTM Revenue (USD) $654M $461M
Market Cap $1.2B $1.6B
3. Profitability & Quality WGS
Gross Margin 19.6% 68.8%
Operating Margin -27.8% -13.7%
Net Profit Margin -22.6% -24.1%
Return on Equity (ROE) -8.9% -41.4%
4. Balance Sheet & Cash Flow WGS
Cash Generation (TTM) -$136M -$101M
Cash Flow Margin -20.8% -22.0%
Net Cash / Leverage $125M Net Debt (0.46x D/E) $119M Net Debt (0.88x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning WGS
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 58.9% (3rd %ile) 102.3% (21st %ile)
Put/Call OI Skew N/A 7.82x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat WGS
OpEx & R&D Intensity 47.4% of Rev ($310M) 82.5% of Rev ($380M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OPK (5) vs WGS (5)
Institutional Metric OPK WGS Criterion Row Edge
Market Capitalization
Scale
$1.2B $1.6B Larger Scale WGS
Trailing P/E Ratio
Valuation
53.8x 38.8x Lower Multiple WGS
Forward P/E Ratio
Valuation
53.8x 40.6x Lower Multiple WGS
Revenue Growth (YoY)
Growth
+15.9% +5.4% Higher Growth OPK
Operating Margin (TTM)
Profitability
-27.8% -13.7% Higher Margin WGS
Net Profit Margin
Profitability
-22.6% -24.1% Higher Margin OPK
Return on Equity (ROE)
Capital Efficiency
-8.9% -41.4% Higher ROE OPK
52-Week Range Position
Momentum
73% ($1–$2) 14% ($32–$171) Stronger Trend OPK
Beta / 30D Volatility
Risk Regime
0.77β · 31% Vol 1.74β · 111% Vol Lower Realized Risk OPK
Unified Institutional Score
Composite Signal
38.6 / 100 (SELL) 49.5 / 100 (HOLD) Higher Composite WGS
Trailing 12M Revenue (USD)
Operating Scale
$654M $461M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
19.6% 68.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.1x EV/Rev N/M PEG · 3.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$136M ($125M Net Debt (0.46x D/E)) -$101M ($119M Net Debt (0.88x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OPK +25.67 pp
OPK: +5.88% · WGS: -19.79%
3M Horizon OPK +52.29 pp
OPK: +19.12% · WGS: -33.17%
6M Horizon OPK +23.85 pp
OPK: +43.36% · WGS: +19.51%
1Y Horizon OPK +87.42 pp
OPK: +26.56% · WGS: -60.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OPK Revenue WGS Revenue OPK Op. Margin WGS Op. Margin Margin Leader
FY2018 $990M N/A -17.3% N/A OPK
FY2019 $900M $200M -30.4% -15.5% WGS
FY2020 $1.44B $180M 4.0% -134.9% OPK
FY2021 $1.77B $210M 1.1% -210.3% OPK
FY2022 $1.00B $230M -22.5% -284.5% OPK
FY2023 $860M $200M -18.2% -89.2% OPK
FY2024 $710M $310M -21.3% -7.6% WGS
FY2025 $610M $430M -19.3% -3.1% WGS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OPK CONSOLIDATION
78d in phase · OBV DISTRIBUTION
Current IV 58.9%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OPK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
WGS BREAKDOWN
96d in phase · OBV DISTRIBUTION
Current IV 102.3%
IV Percentile 21st %ile
Put/Call OI Skew 7.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact WGS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OPK Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $1.2B market capitalization and -27.8% operating margin.
OpEx & R&D Reinvestment 47.4% of Rev ($310M)
90D Engineering Disclosures 0 Published
WGS Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $1.6B market capitalization and -13.7% operating margin.
OpEx & R&D Reinvestment 82.5% of Rev ($380M)
90D Engineering Disclosures 0 Published

Investor FAQ OPK vs WGS Key Questions & Quantitative Answers

As of Nov 16, 2026, Opko Health Inc. (OPK) captures the overall head-to-head institutional edge over GeneDx Holdings Corp. (WGS) on higher Unified Composite conviction (38.6/100 SELL vs. 49.5/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale), while WGS wins 5–1 across the 6-pillar growth and valuation breakdown. OPK trades at $1.62 (53.8x Forward P/E, -27.8% operating margin) versus WGS at $51.02 (40.6x Forward P/E, -13.7% operating margin). Composite vs. Pillar Nuance: While WGS currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. OPK 38.6/100 SELL), OPK captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (-27.8% vs. -13.7% operating margin) and revenue trajectory (+15.9% vs. +5.4% YoY). Technical & Structure Timing Caution: OPK trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.0); meanwhile WGS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OPK leads the Growth & Scale pillar: OPK posts +15.9% YoY revenue growth and -12.6% YoY earnings growth on $654M TTM revenue (19.6% gross margin, -27.8% operating margin), compared with WGS at +5.4% YoY revenue growth and +0.0% YoY earnings growth on $461M TTM revenue (68.8% gross margin, -13.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), OPK cumulative revenue shifted -38.4% while WGS shifted +115.0%. In operating R&D and SG&A reinvestment, OPK deploys 47.4% of Rev ($310M) (0 90-day corporate R&D disclosures) versus 82.5% of Rev ($380M) (0 disclosures) for WGS.

WGS screens cheaper on headline valuation multiples. OPK trades at 53.8x Forward P/E, 53.8x Trailing P/E, N/M PEG, and 2.1x EV/Revenue (-20.8% FCF margin), whereas WGS trades at 40.6x Forward P/E, 38.8x Trailing P/E, N/M PEG, and 3.7x EV/Revenue (-22.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OPK (-8.9% ROE) versus WGS (-41.4% ROE) capital efficiency.

In options market volatility and institutional positioning, OPK carries 58.9% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.77β · 31% Vol realized risk). By comparison, WGS carries 102.3% implied volatility (21st %ile, Compressed (<25th %ile)), a 7.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.74β · 111% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.